JNJ.BA Johnson & Johnson Co DRC
- Market cap
- ARS 365T
- P/E
- 16.0x
- P/B
- 2.88x
- ROE
- 18.0%
- Dividend yield
- -
- Fundamental score
- 2.9/5
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is JNJ.BA undervalued?
Graham numberJNJ.BA trades 42.8% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Johnson & Johnson Co DRC fundamental analysis
15 of 22 checks passedROE 1/2
Moderate return on equity (18.0%), between 10% and 20%.
ROA 1/1
Return on assets (7.4%) is above the industry median (5.6%).
Profit Consistency 2/2
Profitable for 8 consecutive years.
Earnings Growth 5Y 1/1
Earnings per share grew over the past 5 years.
Earnings Acceleration 1/1
Last year's EPS growth (90.5%) is above the 5-year average (14.8% a year).
Earnings Growth vs Industry 1/1
Last year's EPS growth (90.5%) is above the industry median (-3.6%).
Revenue Growth 0/2
Revenue shrank 0.3% a year over the past 3 years.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 0/1
Current assets do not cover long-term liabilities.
Debt to Equity 1/2
Moderate debt to equity (43.9%), up to 100%.
Debt Trend 1/1
Debt to equity has not risen over the past 5 years.
Debt Coverage 1/1
Operating cash flow covers 20% of total debt.
Interest Coverage 1/1
EBIT is 17.6x against interest expense, well covered.
PE vs Market 0/1
PE (16.0x) is above the market median (6.7x).
PE vs Industry 0/1
PE (16.0x) is above the industry median (5.8x).
PBV 0/1
Price to book (2.9x) is above the industry median (0.8x).
Graham Number 0/1
The price is above the Graham number (PE x PB = 45.9, limit 22.5).
PEG 0/1
PEG on 5-year earnings growth is 1.08, above 1.
Dividend Yield 1/2
Dividend yield (2.9%) is above the bottom 25% of dividend payers in the market.
Dividend Stability 1/2
Dividends paid without a cut of more than 10% for 8 years.
Dividend Growth 1/1
Dividends paid grew over the past 5 years.
Payout Ratio 1/1
Payout ratio is 46.2%, covered by earnings.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Johnson & Johnson Co DRC stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Johnson & Johnson Co DRC
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers,…
Full company profileJohnson & Johnson Co DRC financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Johnson & Johnson Co DRC annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | 81.6B | 82.1B | 82.6B | 93.8B | 94.9B | 85.2B | 88.8B | 94.2B | 99.7B |
| Gross Profit | 54.5B | 54.5B | 54.2B | 63.9B | 63.9B | 58.6B | 61.4B | 63.9B | 67.4B |
| Operating Income | 21.2B | 21.0B | 19.9B | 24.5B | 23.7B | 22.0B | 21.2B | 25.6B | 26.6B |
| EBITDA | 25.9B | 24.7B | 23.9B | 30.3B | 26.6B | 23.3B | 24.8B | 41.1B | 26.2B |
| Net Income | 15.3B | 15.1B | 14.7B | 20.9B | 17.9B | 35.2B | 14.1B | 26.8B | 14.6B |
| EPS | 5.75 | 5.74 | 5.59 | 7.94 | 6.86 | 15 | 5.84 | 11 | 6.08 |
| Balance Sheet | |||||||||
| Total Assets | 153B | 158B | 175B | 182B | 187B | 168B | 180B | 199B | 197B |
| Total Liabilities | 93.2B | 98.3B | 112B | 108B | 111B | 98.8B | 109B | 118B | 116B |
| Shareholders' Equity | 59.8B | 59.5B | 63.3B | 74.0B | 76.8B | 68.8B | 71.5B | 81.5B | 81.5B |
| Cash & Short-term Investments | 18.1B | 17.3B | 14.0B | 14.5B | 14.1B | 21.9B | 24.1B | 19.7B | 16.9B |
| Cash Flow | |||||||||
| Operating Cash Flow | 22.2B | 23.4B | 23.5B | 23.4B | 21.2B | 20.3B | 24.3B | 24.5B | 25.1B |
| Capital Expenditure | 3.67B | 3.50B | 3.35B | 3.65B | 4.01B | 4.54B | 6.21B | 5.22B | 6.30B |
| Free Cash Flow | 18.5B | 19.9B | 20.2B | 19.8B | 17.2B | 15.7B | 18.1B | 19.3B | 18.8B |
| Ratios | |||||||||
| ROE | 25.6% | 25.4% | 23.3% | 28.2% | 23.4% | 51.1% | 19.7% | 32.9% | 18.0% |
| ROA | 10.0% | 9.6% | 8.4% | 11.5% | 9.6% | 21.0% | 7.8% | 13.5% | 7.4% |
| Net Profit Margin | 18.8% | 18.4% | 17.8% | 22.3% | 18.9% | 41.3% | 15.8% | 28.5% | 14.7% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Johnson & Johnson Co DRC dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- 46.2%
- Ex-dividend date
- Nov 24, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | USD 12.4B | 5.14 | 46.2% |
| 2024 | USD 11.8B | 4.91 | 84.1% |
| 2023 | USD 11.9B | 4.93 | 33.7% |
| 2022 | USD 11.7B | 4.47 | 65.1% |
| 2021 | USD 11.0B | 4.20 | 52.8% |
| 2020 | USD 10.5B | 3.98 | 71.2% |
| 2019 | ARS 9.92B | 3.77 | 65.6% |
| 2018 | ARS 9.49B | 3.57 | 62.1% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Johnson & Johnson Co DRC
- Insiders 0.00%
- Institutions 0.06%
- Public & others 99.94%
- Shares outstanding 12.0B
- Free float 35.9B
Johnson & Johnson Co DRC company profile
- Company name
- Johnson & Johnson Co DRC
- Ticker
- JNJ.BA
- ISIN
- ARDEUT110236
- Exchange
- Buenos Aires Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 138,200
- Fiscal year end
- December
- Address
- One Johnson & Johnson Plaza, New Brunswick, NJ, United States, 08933
- Phone
- 732 524 0400
- Website
- jnj.com
About Johnson & Johnson Co DRC
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.
Johnson & Johnson Co DRC management
10- Mr. Joaquin DuatoCEO & Chairman · born 1963
- Mr. Joseph James Wolk CPAExecutive VP & CFO · born 1967
- Dr. John C. Reed M.D., Ph.D.Executive Vice President of Innovative Medicine and R&D · born 1958
- Mr. Timothy SchmidExecutive VP & Worldwide Chairman of MedTech · born 1970
- Mr. Robert J. Decker Jr.Controller & Chief Accounting Officer · born 1973
- Mr. James SwansonExecutive VP & Chief Information Officer · born 1966
- Mr. Ryan KoorsVice President of Investor Relations
- Mr. Dirk BrinckmanChief Compliance Officer
- Ms. Elizabeth Forminard J.D.Executive VP & Chief Legal Officer · born 1971
- Ms. Kristen Blair MulhollandExecutive VP & Chief Human Resources Officer · born 1967